Structural Formula (7b6280e3 Cbeb 4385 8ab8 263e4405cb6c 01)
Tacrolimus Ointment
Product Images NDC 45802-390
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tacrolimus (NDC 45802-390). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Padagis Israel Pharmaceuticals Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Table 1 (7b6280e3 Cbeb 4385 8ab8 263e4405cb6c 02)
This text provides data on the Global Improvement over Baseline at the End-Of-Treatment in Three Phase 3 Studies involving a Pediatric Study and Adult Studies, where patients were treated with Tacrolimus Ointment at different concentrations. The text presents the percentage improvement observed in the different treatment groups, as well as the number of patients evaluated in each group.*
Figures 1 And 2 (7b6280e3 Cbeb 4385 8ab8 263e4405cb6c 03)
The text is a mix of gibberish and incomplete information. It is not available.*
Figures 3 And 4 (7b6280e3 Cbeb 4385 8ab8 263e4405cb6c 04)
The text describes figures 3 and 4, which show the mean erythema (redness of the skin) over time for adult and pediatric patients. The figures include a graph with the mean erythema score and 95% confidence intervals plotted against time in weeks. However, there is not enough information to determine the context or purpose of the study.*
Table 2 (7b6280e3 Cbeb 4385 8ab8 263e4405cb6c 05)
This data presents the duration of follow-up in four open-label safety studies for both adults and pediatrics. It shows the number of participants in each category based on the time spent in the study, which is divided into four stages: less than one year, more than one year, more than two years, and exactly three years. The data is presented separately for adults and pediatrics, as well as the total number of participants in the study.*
Table 3 (7b6280e3 Cbeb 4385 8ab8 263e4405cb6c 06)
The text appears to be a table indicating the incidence rate (%) of treatment emergent adverse events in studies involving Tacrolimus Ointment. The data have been sorted by adverse events and categorized by adult and pediatric participants. The table also shows the study length, number of participants and an adjusted incidence rate (%).*
Lion (Lion)
Carton 30g 03
This is the packaging and product information of Tacrolimus Ointment, which contains 0.03% of tacrolimus, manufactured by Fermigo and distributed by Perrigo. It is for dermatologic use only and contains several ingredients such as mineral oil, paraffin, and propylene carbonate. The medication guide must be dispensed along with the product. It should be stored at room temperature, and the dosage information can be found in the package insert.*
Carton 30g 1
This is a description for Tacrolimus Ointment with NDC code 45802-700-00 manufactured by Perrigo Laboratories. It is intended for dermatologic use only and contains 0.1% tacrolimus in a mineral oil base with additional ingredients. The ointment should be stored at room temperature, and the package insert should be consulted for dosage information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
